Skip to content
value.today
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

Formerly Aligos, Inc.

Total raised
$85 M
1 round on record
Latest round
$85 M
Dec 2019
First round on record
Dec 2019
Today
Went public
See the company page

Aligos Therapeutics, Inc. is listed today as Aligos Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Aligos Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$105 MPrivate placement after listing$50 to $250 million

Aligos Therapeutics, Inc.: Private sale, Feb 2025

Investors in this round

12 investors had bought by the notice of Feb 28, 2025: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Aligos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$105 M of $105 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,700,192
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hardean Peter Achneck · Executive Officer
  • Julian Peter Symons · Executive Officer
  • Lawrence M. Blatt · Executive Officer, Director · President and Chief Executive Officer
  • Lesley Ann Calhoun · Executive Officer · Executive Vice President, Chief Operating Officer and Chief Financial Officer
  • Bridget Peter Martell · Director
  • Carole Peter Nuechterlein · Director
  • Heather Peter Preston · Director
  • James Peter Scopa · Director
  • K. Peter Hirth · Director
  • Margarita Peter Chavez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Sandler & Co. · Minneapolis, MinnesotaSold in all US states
  • Jefferies LLC · New York, New YorkSold in all US states

Signed by Lawrence M. Blatt, President and Chief Executive Officer. Newest notice filed Feb 28, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2023$92 MPrivate placement after listing$50 to $250 million

Aligos Therapeutics, Inc.: Private sale, Oct 2023

Investors in this round

11 investors had bought by the notice of Nov 7, 2023: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Aligos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$92 M of $92 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,529,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julian Ann Symons · Executive Officer · Executive Vice President, Chief Scientific Officer
  • Lawrence Blatt · Executive Officer, Director · Chief Executive Officer
  • Leonid Beigelman · Executive Officer, Director · President
  • Lesley Ann Calhoun · Executive Officer · Executive Vice President, Chief Financial Officer
  • Lucinda Ann Quan · Executive Officer · Executive Vice President, Chief Business Officer and General Counsel
  • Matthew Ann McClure · Executive Officer · Executive Vice President, Chief Medical Officer
  • Bridget Ann Martell · Director
  • Carole Ann Nuechterlein · Director
  • Jack Ann Nielsen · Director
  • James Ann Scopa · Director
  • Peter Ann Hirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • PIPER SANDLER & CO. (CRD 665) · Minneapolis, MinnesotaSold in all US states

Signed by Lawrence Blatt, Chief Executive Officer. Newest notice filed Nov 7, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2019$85 MNo. 1$50 to $250 million

Aligos Therapeutics, Inc.: Raise no. 1, Dec 2019

Investors in this round

38 investors had bought by the notice of Jan 16, 2020: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Aligos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $125 M offered; $40 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Dowd · Executive Officer · Executive Vice President - Controller
  • John Fry · Executive Officer · Executive Vice President - Clinical Development
  • Julian Symons · Executive Officer · Executive Vice President - Chief Scientific Officer
  • Lawrence Blatt · Executive Officer, Director · Chief Executive Officer
  • Leonid Beigelman · Executive Officer, Director · President
  • Lucinda Quan · Executive Officer · Executive Vice President - General Counsel
  • Sushmita Chanda · Executive Officer · Executive Vice President - Preclinical Development
  • Carole Neuchterlein · Director
  • Jack Nielsen · Director
  • Kathleen Glaub · Director
  • Michael Yi · Director
  • Peter Hirth · Director
  • Peter Moldt · Director
  • Tom Woiwode · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lawrence Blatt, Chief Executive Officer. Newest notice filed Jan 16, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aligos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).

    SEC Form D · Feb 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2025

Products and services#

No products or services of Aligos Therapeutics, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Aligos Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Julian A. SymonsPersonnot statednot statedHeld Series A, B-1 and B-2 preferred stock (Form 3, 2020)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Vantage I, L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Versant Venture Capital VI, L.P.Venture capitalnot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series B-1 and B-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Largest shareholders today

Institutions holding Aligos Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aligos Therapeutics, Inc.
NameRoleNamed in
Hardean Peter AchneckExecutive officerFeb 2025
Julian Peter SymonsExecutive officerFeb 2025
Lawrence M. BlattPresident and Chief Executive OfficerFeb 2025
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer and Chief Financial OfficerFeb 2025
Julian Ann SymonsExecutive Vice President, Chief Scientific OfficerNov 2023
Lawrence BlattChief Executive OfficerNov 2023
Leonid BeigelmanPresidentNov 2023
Lucinda Ann QuanExecutive Vice President, Chief Business Officer and General CounselNov 2023
Matthew Ann McClureExecutive Vice President, Chief Medical OfficerNov 2023
Brian DowdExecutive Vice President - ControllerJan 2020
John FryExecutive Vice President - Clinical DevelopmentJan 2020
Julian SymonsExecutive Vice President - Chief Scientific OfficerJan 2020
Lucinda QuanExecutive Vice President - General CounselJan 2020
Sushmita ChandaExecutive Vice President - Preclinical DevelopmentJan 2020
Bridget Peter MartellDirectorFeb 2025
Carole Peter NuechterleinDirectorFeb 2025
Heather Peter PrestonDirectorFeb 2025
James Peter ScopaDirectorFeb 2025
K. Peter HirthDirectorFeb 2025
Lawrence M. BlattPresident and Chief Executive OfficerFeb 2025
Margarita Peter ChavezDirectorFeb 2025
Bridget Ann MartellDirectorNov 2023
Carole Ann NuechterleinDirectorNov 2023
Jack Ann NielsenDirectorNov 2023
James Ann ScopaDirectorNov 2023
Lawrence BlattChief Executive OfficerNov 2023
Leonid BeigelmanPresidentNov 2023
Peter Ann HirthDirectorNov 2023
Carole NeuchterleinDirectorJan 2020
Jack NielsenDirectorJan 2020
Kathleen GlaubDirectorJan 2020
Michael YiDirectorJan 2020
Peter HirthDirectorJan 2020
Peter MoldtDirectorJan 2020
Tom WoiwodeDirectorJan 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.